Rebiotix Completes Enrollment In Phase 2 Clinical Trial Of New Drug For The Treatment Of Recurrent Clostridium Difficile-Associated Diarrhea
1/13/2014 11:12:19 AM
ROSEVILLE, Minn.--(BUSINESS WIRE)--Rebiotix Inc. has announced that it has completed enrollment in the PUNCH™ CD Phase 2 clinical trial of RBX2660 (microbiota suspension) for the treatment of recurrent Clostridium difficile-associated diarrhea (CDAD). The study is the first of its kind prospective, multicenter clinical study to evaluate a non-antibiotic, live microbial drug product for the treatment of recurrent CDAD conducted using the same protocol at all sites.
Help employers find you! Check out all the jobs and post your resume.
comments powered by